Cosmederm Bioscience’s Tri-Calm OTC itch relief solution is quickly climbing the anti-itch treatment product chart with growth of 148.2% to a dollar base of $4.9 million for the 52 weeks ended June 14 across total U.S. multi-outlets, according to IRI.
Cosmederm Bioscience’s TriCalm OTC itch-relief solution was recognized in May by the journal Clinical, Cosmetic and Investigational Dermatology,, which published a study finding that Cosmederm’s solution was superior to diphenhydramine 2% and hydrocortisone 1%.
Cosmederm Bioscience announced that a study recently published in the journal Acta Dermato-Venereologica has established its TriCalm anti-itch product has greater anti-itch efficacy as compared with products containing hydrocortisone or diphenhydramine.
AccuDial Pharmaceutical recently launched four products as part of its Go-Green pediatric liquid cough-cold lineup that features dosing information on a rotating label, a larger 6-point font and a dosing cup that's shrink-wrapped to the top of the container.
The U.S. Pharmacopeial Convention last week announced that it is working with the Food and Drug Administration and the Consumer Healthcare Products Association to update quality standards for widely used medicines and ingredients. Updated test methodologies are crucial to help counter economically motivated adulteration — in which less expensive and potentially harmful ingredients are substituted for genuine medicines or their ingredients — and also to address the challenge of impurities that may go undetected with older, nonspecific assays and tests.